Why it matters: Johnson & Johnson has dramatically escalated its Washington influence campaign, increasing lobbying expenditures by nearly 120% compared to last quarter. The surge signals urgent priorities for the healthcare giant as key drug pricing and intellectual property bills advance through Congress.
By the numbers: J&J reported spending $3.34 million on federal lobbying in Q1 2025, up from $1.52 million in Q4 2024, according to recent disclosure filings. This represents the company’s most significant quarterly lobbying investment in years, far exceeding its historical average of $1.56 million per quarter.
The big picture: The healthcare behemoth is targeting multiple fronts simultaneously, with particular focus on modifying the Inflation Reduction Act’s drug pricing provisions and reshaping patent legislation that could affect pharmaceutical competition.
Driving the agenda: J&J’s top legislative priorities reveal a company fighting to protect its business model:
-
Drug pricing reform modifications: J&J is lobbying on the ORPHAN Cures Act and EPIC Act, both aimed at softening the IRA’s Medicare drug price negotiation requirements.
-
Patent and competition battles: The company is heavily engaged on three Senate bills that recently advanced to the floor calendar: Drug Competition Enhancement Act (targeting "product hopping"), the Affordable Prescriptions for Patients Act, and the Interagency Patent Coordination Act.
-
Diverse portfolio: Additional focus areas include medical device electronic labeling, patient copay assistance programs, healthcare worker support, and emerging technology regulations.
Between the lines: J&J’s lobbying surge comes as several pharmaceutical patent bills have advanced from committee to the Senate floor, suggesting the company anticipates crucial legislative battles in the coming months.
Who’s carrying the message: J&J relies on experienced in-house lobbyists with deep government connections, including:
- David Kirk Kavanaugh, former staff on House Ways and Means and Senate HELP committees
- Amy Marie Pellegrino, former Senate HELP Committee Subcommittee Staff Director
- Meghan Drenan Stone, former Legislative Counsel to a House Energy and Commerce Committee member
The opposition: J&J faces resistance from both sides of the aisle. Sen. John Cornyn [R-TX] is leading efforts to curb "product hopping" with his Drug Competition Enhancement Act, while Sen. Richard Durbin [D-IL] champions improved patent transparency between FDA and USPTO.
What to watch: With three key pharmaceutical patent bills now on the Senate legislative calendar and J&J’s dramatic increase in lobbying expenditures, expect intensified pharmaceutical industry presence in Washington as these bills progress toward potential floor votes.
The bottom line: Johnson & Johnson’s unprecedented lobbying investment signals high stakes in current legislative battles that could reshape pharmaceutical pricing, patent protections, and ultimately, the company’s business model for years to come.
Spot something wrong? Report an issue with this article